WSJ cites Novartis setback as warning for pharma M&A
TradingView/WSJ says Novartis’ latest trial setback is being framed as a cautionary tale for investors betting on big pharma’s strategy of bite-size acquisitions to support drug pipelines.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.